Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate

Nature Medicine

Volumn 1, Issue 9, 1995, Pages 944-949

  Nelson, Joel B ^a   Hedican, Sean P ^a   George, Daniel J ^b   Reddi, A H ^b,c   Piantadosi, Steven ^b   Eisenberger, Mario A ^b   Simons, Jonathan W ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ENDOTHELIN 1; MITOGENIC AGENT;

ARTICLE; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; ALKALINE PHOSPHATASE; BASE SEQUENCE; BONE NEOPLASMS; ENDOTHELINS; ENZYME INDUCTION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN; ISCHEMIA; MALE; MIDDLE AGE; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; OSTEOBLASTS; PAIN; PROSTATIC NEOPLASMS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED; VASOCONSTRICTION;

EID: 0029085123     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm0995-944     Document Type: Article

References (65)

1. Wingo, P.A., Tong, T. and Bolden, S. Cancer statistics, 1995. CA Cancer J. Clin. 45, 8-30 (1995).
2. Huggins, C., Stevens, R.E. and Hodges, C.V. Studies on prostate cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch. Surg. 43, 209-223 (1941).
3. Kelly, W.K. et al. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J. din. Oncol. 11, 607-615 (1993).
4. Yanagisawa, M. et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332, 411-415 (1988).
5. Casey, M.L., Byrd, W. and MacDonald, P.C. Massive amounts of immunoreac- tive endothelin in human seminal fluid. J. clin. Endoc. Metabol. 74, 223-225 (1992).
6. Langenstroer, P. etal. Endothelin-1 in the human prostate: tissue levels, source of production and isometric tension studies. J. Urol. 149, 495-499 (1993).
7. Kobayashi, S. et al. Binding and functional properties of endothelin receptor subtypes in the human prostate. Molec. Pharmacol. 45, 306-311 (1994).
8. Kobayashi, S. et al. Localization of endothelin receptors in the human prostate. J. Urol. 151, 763-766 (1994).
9. Muldoon, L.L., Rodland, K.D., Forsythe, M.L. and Magun, B.E. Stimulation of phosphatidylinositol hydrolysis, diacylglycérol release, and gene expression in response to endothelin, a potent new agonist for fibroblasts and smooth muscle cells. J. biol. Chem. 264, 8529-8536 (1989).
10. Brown, K.D. and Littlewood, C.J. Endothelin stimulates DNA synthesis in Swiss 3T3 cells: Synergy with polypeptide growth factors. Biochem. J. 263, 977-980 (1989).
11. Shubeita, H.E. et al. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly and cardiac gene expression in ventricular myocytes. J. biol. Chem. 265, 20555-20562 (1990).
12. Battistini, B., Chailler, P., D'Orleans-Juste, P., Briere, N. and Sirois, P. Growth regulatory properties of endothelins. Peptides 14, 385-399 (1993).
13. Schirchiri, M. et al. Endothelin-1 is an autocrineJparacrine growth factor for human cancer cell lines, J. clin. Invest. 87, 1867-1871 (1991).
14. Takuwa, Y., Ohue, Y., Takuwa, N. and Yamashita, K. Endothelin-1 activates phospholipase C and mobilizes Cai+ from extra-and intracellular pools in osteoblastic cells. Am. J. Physiol. 257, E797-803 (1989).
15. Takuwa, Y., Masaki, T, and Yamashita, K, The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae. Biochem. biophys. Res. Commun. 170, 998-1005 (1990).
16. Schvartz, I., Ittoop, O., Davidai, G. and Hazum, E. Endothelin rapidly stimulates tyrosine phosphorylation in osteoblast-like cells. Peptides 13, 159-163 (1992).
17. Shioide, M. and Noda, M. Endothelin modulates osteopontin and osteocalcin messenger ribonucleic acid expression in rat osteoblastic osteosarcoma cells. J. cell. Biochem. 53, 176-180 (1993).
18. Suzuki, N., Matsumoto, H., Kitada, C., Kimura, S. and Fujino, M. Production of endothelin-1 and big-endothelin-1 by tumour cells with epithelial-like morphology. J. Biochem. 106, 736-741 (1989).
19. Kusuhara, M, et al. Production of endothelin in human cancer cell lines. Cancer Res. 50, 3257-3261 (1990).
20. Schrey, M.P., Patel, K.V. and Tezapsidis, N. Bombesin and glucocorticoids stimulate human breast cancer cells to produce endothelin, a paracrine mitogen for breast stromal cells. Cancer Res. 52, 1786-1790 (1992).
21. Economos, K., MacDonald, P.C. and Casey, M.L. Endothelin-1 gene expression and biosynthesis in human endometrial HEC-1A cancer cells. Cancer Res. 52, 554-557 (1992).
22. Yamashita, J. etal. Abundant expression of immunoreactive endothelin-1 in mammary phyllodes tumour: Possible role of endothelin 1 in the growth of stromal cells in phyllodes tumour. Cancer Res. 52, 4046-4049 (1992).
23. Yamashita, J. et al. Interleukin 6 stimulates the production of immunoreactive endothelin 1 in human breast cancer cells. Cancer Res. 53, 464-467 (1993).
24. Inoue, A. et al. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. natn. Acad. Sci. U.S.A. 86, 2863-2867 (1989).
25. Takasaki, C, Yanagisawa, M., Kimura, S., Goto, K. and Masaki, T. Similarity of endothelin to snake venom toxin. Nature 335, 303 (1988).
26. Kochva, E., Bdolah, A. and Wollberg, Z. Sarafotoxins and endothelins: Evolution, structure and function. Toxicon 31, 541-568 (1993).
27. Kochva, E., Viljoen, C.C. and Botes, D.P. A new type of toxin in the venom of snakes of the genus Atractaspis (Atractaspidinae). Toxicon 20, 581-592 (1982).
28. Dahlof, B., Gustafsson, D., Hedner, T., Jern, S. and Hansson, L. Regional haemodynamic effects of endothelin-1 in rat and man: Unexpected adverse reactions. J. Hypertens. 8, 811-817 (1990).
29. Eisenberger, M.A. et al. Suramin, an active drug for prostate cancer: Interim observations in a phase I trial. J. natn. Cancer Inst. 85, 611-621 (1993).
30. Yamane, K. et al. Significance of plasma endothelin-1 levels in patients with systemic sclerosis, J. Rheumatol. 19, 1566-1571 (1992).
31. Ogawa, S., Zhang, J. and Yuge, K. Increased plasma endothelin-1 concentration in Kawasaki disease. J. Cardiovasc. Pharmacol. 22, S364-366 (1993).
32. Cernacek, P. and Stewart, D.J. Immunoreactive endothelin in human plasma: Marked elevations in patients in cardiogenic shock. Biochem. biophys. Res. Commun. 161, 562-567 (1989).
33. Yasuda, M. etal. Circulating immunoreactive endothelin in ischemic heart disease. Am. HeartJ. 119, 801-806 (1990).
34. Lerman, A. et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. New Engl. J. Med. 325, 997-1001 (1991).
35. Yokokawa, K. et al. Hypertension associated with endothelin-secreting malignant hemangioendothelioma. Ann. intern. Med. 114, 213-215 (1991).
36. Yokokawa, K. etal. Endothelin-secreting tumour. J. Cardiovasc. Pharmacol. 17, S398-S401 (1991).
37. Cacoub, P., Dorent, R., Nataf, P. and Carayon, A. Endothelin-1 in pulmonary hypertension. New Engl. J. Med. 329, 1967-1968 (1993).
38. Pittet, J.F. et al. Elevated plasma endothelin-1 concentrations are associated with the severity of illness in patients with sepsis. Ann. Surg. 213, 261-264 (1991).
39. Wei, C.M. et al. Endothelin in human congestive heart failure. Circulation 89, 1580-1586 (1994).
40. Moore, K. et al. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. New Engl. J. Med. 327, 1774-177S (1992).
41. Rolinski, B., Sadri, I., Bogner, J. and Goebel, F.D. Determination of endothelin-1 immunoreactivity in plasma, cerebrospinal fluid and urine. Res. exp. Med. 194, 9-24 (1994).
42. Nakamuta, M. etal. High plasma concentrations of endothelin-Iike immunore- activities in patients with hepatocellular carcinoma. Am. J. Gastroenterol. 88, 248-252 (1993).
43. Moller, S., Emmeluth, C., and Henriksen, J.H. Elevated circulating plasma endothelin-1 concentrations in cirrhosis. J. Hepatol. 19, 285-290 (1993).
44. MacCumber, M.W., Ross, C.A., Glaser B.M. and Snyder, S.H. Endothelin: Visualization of mRNAs by in situ hybridization provides evidence for local action. Proc. natn. Acad. Sci. U.S.A. 86, 7285-7289 (1989).
45. Wagner, O.F. etal. Polar secretion of endothelin-1 by cultured endothelial cells. J. biol. Chem. 267, 16066-16088 (1992).
46. Rubanyi, G.M. and Parker Botelho, L.H. Endothelins. FASEB J. 5, 2713-2720 (1991).
47. Warner, T.D., Battistini, B., Doherty, A.M. and Corder, R. Endothelin receptor antagonists: Actions and rationale for their development. Biochem. Pharmacol. 48, 625-635 (1994).
48. Battistini, B., D'Orleans-Juste, P. and Sirois, P. Endothelins: Circulating plasma levels and presence in other biologic fluids. Lab. Invest. 68, 600-628 (1993).
49. Simonson, M.S. and Dunn, M.J. Cellular signaling by peptides of the endothelin gene family. FASEB J. 4, 2989-3000 (1990).
50. Erdos, E.G., Schulz, W.W., Gafford, J.T. and Defendini, R. Neutral metalloen- dopeptidase in human male genital tract: Comparison to angiotensin I-con-verting enzyme. Lab. Invest. 52, 437-447 (1985).
51. Papandreou, C. et al. Loss of neutral endopeptidase in androgen independent prostate cancers. Proc. Am. Assoc. Cancer Res. 36, 268 (1995).
52. Stamey, T.A. et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. New Engl. J. Med. 317, 909-916 (1987).
53. Oesterling, J.E. et al. Prostate-specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J. Urol. 139, 766-779 (1988).
54. Rubin, S.A. and Levin, E.R. The endocrinology of vasoactive peptides: Synthesis to function. J. din. Endocr. Metabol. 78, 6-10 (1994).
55. Polderman, K.H. et al. Influence of sex hormones on plasma endothelin levels. Ann. intern. Med. 118, 429-432 (1993).
56. Scher, H.I. and Chung, L.W.K. Bone métastasés: Improving the therapeutic index. Semin. Oncol. 21, 630-656 (1994).
57. Alam, A.S.M.T. etal. Endothelin inhibits osteoclastic bone resorption by a direct effect on cell motility: Implications for the vascular control of bone resorption. Endocrinology 130, 3617-3624 (1992).
58. Charache, S. and Page, D.L. Infarction of bone marrow in the sickle cell disorders. Ann. intern. Med. 67, 1195-1200 (1967).
59. Platt, O.S. et al. Pain in sickle cell disease: Rates and risk factors. New Engl. J. Med. 325, 11-16(1991).
60. Lam, H.C. et al. Immunoreactive endothelin in human plasma, urine, milk, and saliva. J. Cardiovasc. Pharmacol. 17, S390-393 (1991).
61. Reddi, A.H. and Huggins, C. Biochemical sequences in the transformation of normal fibroblasts in adolescent rats. Proc. naùi. Acad. Sci. U.S.A. 69, 1601-1605 (1972).
62. Reddi, A.H. and Sullivan, N.E. Matrix-induced endochondral bone differentiation influence of hypophysectomy, growth hormone, and thyroid-stimulating hormone. Endocrinology 107, 1291-1299 (1980).
63. Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall, R.J. Protein measurement with the Folin phenol reagent. J. biol. Chem. 193, 265 (1951).
64. Kramer, C.Y. Extension of multiple range tests to group means with unequal numbers of replications. Biometrics 12, 307-310 (1956).
65. Kruskal, W.H. and Wallis, W.A. Use of ranks in one-criterion variance analysis. J. Am. Stat. Assoc. 47, 583-621 (1952). Addendum, J. Am. Stat. Assoc. 48, 907-911 (1953).